Lyra Therapeutics Inc (LYRA) has a current Price-to-Book (P/B) ratio of -1.20. Compared to its 3-year average P/B ratio of 1.73, the current P/B ratio is approximately -169.55% higher. Relative to its 5-year average P/B ratio of 1.76, the current P/B ratio is about -168.26% higher. Lyra Therapeutics Inc (LYRA) has a Forward Free Cash Flow (FCF) yield of approximately -608.12%. Compared to its 3-year average FCF yield of -316.73%, the current FCF yield is approximately 92.00% lower. Relative to its 5-year average FCF yield of -197.48%, the current FCF yield is about 207.94% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for LYRA competitors is 1.07, providing a benchmark for relative valuation. Lyra Therapeutics Inc Corp (LYRA.O) exhibits a P/S ratio of 5.34, which is 400% above the industry average. Given its robust revenue growth of -87.18%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of LYRA increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of LYRA in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is LYRA currently overvalued or undervalued?

What is Lyra Therapeutics Inc (LYRA) fair value?

LYRA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Lyra Therapeutics Inc (LYRA) is between 0.91 to 2.81 according to relative valuation method.

How does LYRA's valuation metrics compare to the industry average?

The average P/S ratio for LYRA's competitors is 1.07, providing a benchmark for relative valuation. Lyra Therapeutics Inc Corp (LYRA) exhibits a P/S ratio of 5.34, which is 400.00% above the industry average. Given its robust revenue growth of -87.18%, this premium appears unsustainable.

What is the current P/B ratio for Lyra Therapeutics Inc (LYRA) as of Mar 04 2026?

As of Mar 04 2026, Lyra Therapeutics Inc (LYRA) has a P/B ratio of -1.20. This indicates that the market values LYRA at -1.20 times its book value.

What is the current FCF Yield for Lyra Therapeutics Inc (LYRA) as of Mar 04 2026?

As of Mar 04 2026, Lyra Therapeutics Inc (LYRA) has a FCF Yield of -608.12%. This means that for every dollar of Lyra Therapeutics Inc's market capitalization, the company generates -608.12 cents in free cash flow.

What is the current Forward P/E ratio for Lyra Therapeutics Inc (LYRA) as of Mar 04 2026?

As of Mar 04 2026, Lyra Therapeutics Inc (LYRA) has a Forward P/E ratio of -0.38. This means the market is willing to pay $-0.38 for every dollar of Lyra Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Lyra Therapeutics Inc (LYRA) as of Mar 04 2026?

As of Mar 04 2026, Lyra Therapeutics Inc (LYRA) has a Forward P/S ratio of 5.34. This means the market is valuing LYRA at $5.34 for every dollar of expected revenue over the next 12 months.

LYRA Valuation